The Early Phase Clinical Cancer Prevention Consortium (ClinCaP) is one of the five consortia within the Cancer Prevention Clinical Trials Network (CP-CTNet). This network was established by the National Cancer Institute, Division of Cancer Prevention to spur the development of new cancer preventive agents. The charge of the network is to conduct Phase I and II trials of new preventive agents, and the results of the early phase trials inform optimize the dosing and biomarkers for use in subsequent Phase III Trials. The Lead Academic Organization (LAO) for ClinCap is the University of Michigan, and institutions across the country participate within ClinCaP.
The dual Principal Investigators of ClinCaP are Scott Schuetze, MD, PhD, and Zora Djuric, PhD, at the University of Michigan. The organ-based working groups are charged with developing new trials. Ananda Sen, PhD, provides assistance with biostatistical aspects of trials. Stephen Kress, Gina Vincent and Dominique Bounds are responsible for multi-site management.
Dual PIs: Scott Schuetze, MD, PhD, & Zora Djuric, PhD (U Michigan)
Lower GI Working Group: Carol Burke, MD (Cleveland Clinic)
Upper GI Working Group: Amitabh Chak, MD (Case Western Reserve U)
GU Working Group: Steven Clinton, MD, PhD (Ohio State U)
Breast Working Group: C. Fabian, MD & B. Kimler, PhD (U Kansas)
Biostatistics Support: Ananda Sen, PhD (U Michigan)
Multi-Site Trial Manager: Stephen Kress (U Michigan)
Multi-Site Trial Coordinators: Dominique Bounds and Gina Vincent (U Michigan)
The ClinCaP has established a process for investigators who wish to develop new concepts for trials.
